Citations

Showing 10 of 108152 citations.

Rule-Based Cohort Definitions for Acute Respiratory Distress Syndrome: A Computable Phenotyping Strategy Based on the Berlin Definition
Li, Heyi , Odeyemi, Yewande , Weister, Timothy J. , Liu, Chang , Chalmers, Sarah , Lal, Amos , Song, Xuan , Odeyemi, Yewande E, Chalmers, Sarah J, Lal, Amos , Gajic, Ognjen , Kashyap, Rahul

Mayo Clinic

Critical Care Explorations | June 11, 2021 | Volume: 3 | Issue: 6 | Pages: e0451

10.1097/cce.0000000000000451 | PMID 34136825 Get It

OBJECTIVES: Accurate identification of acute respiratory distress syndrome is essential for understanding its epidemiology, patterns of care, and outcomes. We aimed to design a computable phenotyping strategy to detect acute respiratory distress syndrome in electronic health records of critically ill patients. DESIGN: This is a retrospective cohort study. Using a near real-time copy of the electronic health record, we developed a computable phenotyping strategy to detect acute respiratory distress syndrome based on the Berlin definition. SETTING: Twenty multidisciplinary ICUs in Mayo Clinic Health System. SUBJECTS: The phenotyping strategy was applied to 196,487 consecutive admissions from year 2009 to 2019. INTERVENTIONS: The acute respiratory distress syndrome cohort generated by this novel strategy was compared with the acute respiratory distress syndrome cohort documented by clinicians during the same period. The sensitivity and specificity of the phenotyping strategy were calculated in randomly selected patient cohort (50 patients) using the results from manual medical record review as gold standard. MEASUREMENTS AND MAIN RESULTS: Among the patients who did not have acute respiratory distress syndrome documented, the computable phenotyping strategy identified 3,169 adult patients who met the Berlin definition, 676 patients (21.3%) were classified to have severe acute respiratory distress syndrome (Pao 2/Fio 2 ratio ≤ 100), 1,535 patients (48.4%) had moderate acute respiratory distress syndrome (100 < Pao 2/Fio 2 ratio ≤ 200), and 958 patients (30.2%) had mild acute respiratory distress syndrome (200 < Pao 2/Fio 2 ratio ≤ 300). The phenotyping strategy achieved a sensitivity of 94.4%, specificity of 96.9%, positive predictive value of 94.4%, and negative predictive value of 96.9% in a randomly selected patient cohort. The clinicians documented acute respiratory distress syndrome in 1,257 adult patients during the study period. The clinician documentation rate of acute respiratory distress syndrome was 28.4%. Compared with the clinicians’ documentation, the phenotyping strategy identified a cohort that had higher acuity and complexity of illness suggested by higher Sequential Organ Failure Assessment score (9 vs 7; p < 0.0001), higher Acute Physiology and Chronic Health Evaluation score (76 vs 63; p < 0.0001), higher rate of requiring invasive mechanical ventilation (99.1% vs 71.8%; p < 0.0001), higher ICU mortality (20.6% vs 16.8%; p < 0.0001), and longer ICU length of stay (5.1 vs 4.2 d; p < 0.0001). CONCLUSIONS: Our rule-based computable phenotyping strategy can accurately detect acute respiratory distress syndrome in critically ill patients in the setting of high clinical complexity. This strategy can be applied to enhance early recognition of acute respiratory distress syndrome and to facilitate best-care delivery and clinical research in acute respiratory distress syndrome.
Clinical and Functional Characterization of Atypical KRAS / NRAS Mutations in Metastatic Colorectal Cancer
Loree, Jonathan M. , Wang, Yucai , Syed, Muddassir, Sorokin, Alexey V. , Coker, Oluwadara , Xiu, Joanne , Weinberg, Benjamin A. , Vanderwalde, Ari M. , Tesfaye, Anteneh , Raymond, Victoria M. , Miron, Benjamin , Tarcic, Gabi , Zelichov, Ori, Broaddus, Russell R. , Ng, Patrick Kwok Shing , Jeong, Kang Jin , Tsang, Yiu Huen , Overman, Michael J. , Mills, Gordon B , Overman, Michael J , Marshall, John L , Raymond, Victoria M , Wang, Yucai , VanderWalde, Ari , Loree, Jonathan M , Mills, Gordon B. , Grothey, Axel , Kopetz, Scott

Mayo Clinic

Clinical Cancer Research | June 11, 2021 | Volume: 27 | Issue: 16 | Pages: 4587-4598

10.1158/1078-0432.ccr-21-0180 | PMID 34117033 Get It

Abstract Purpose: Mutations in KRAS/NRAS (RAS) predict lack of anti-EGFR efficacy in metastatic colorectal cancer (mCRC). However, it is unclear if all RAS mutations have similar impact, and atypical mutations beyond those in standard guidelines exist. Experimental Design: We reviewed 7 tissue and 1 cell-free DNA cohorts of 9,485 patients to characterize atypical RAS variants. Using an in vitro cell-based assay (functional annotation for cancer treatment), Ba/F3 transformation, and in vivo xenograft models of transduced isogenic clones, we assessed signaling changes across mutations. Results: KRAS exon 2, extended RAS, and atypical RAS mutations were noted in 37.8%, 9.5%, and 1.2% of patients, respectively. Among atypical variants, KRAS L19F, Q22K, and D33E occurred at prevalence ≥0.1%, whereas no NRAS codon 117/146 and only one NRAS codon 59 mutation was noted. Atypical RAS mutations had worse overall survival than RAS/BRAF wild-type mCRC (HR, 2.90; 95% confidence interval, 1.24–6.80; P = 0.014). We functionally characterized 114 variants with the FACT assay. All KRAS exon 2 and extended RAS mutations appeared activating. Of 57 atypical RAS variants characterized, 18 (31.6%) had signaling below wild-type, 23 (40.4%) had signaling between wild-type and activating control, and 16 (28.1%) were hyperactive beyond the activating control. Ba/F3 transformation (17/18 variants) and xenograft model (7/8 variants) validation was highly concordant with FACT results, and activating atypical variants were those that occurred at highest prevalence in clinical cohorts. Conclusions: We provide best available evidence to guide treatment when atypical RAS variants are identified. KRAS L19F, Q22K, D33E, and T50I are more prevalent than many guideline-included RAS variants and functionally relevant.
Impact of Cancer and Cardiovascular Disease on In-Hospital Outcomes of COVID-19 Patients: Results From the American Heart Association COVID-19 Cardiovascular Disease Registry
Tehrani, David M. , Wang, Xiaoyan , Rafique, Asim , Herrmann, Joerg , Neilan, Tomas G. , Desai, Pooja , Parikh, Rushi V. , Hayek, Salim S. , Morgans, Alicia K. , Lopez‐Mattei, Juan , Yang, Eric H.

Mayo Clinic

No container title available | June 11, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-600795/v1 | PMID 34127966 Get It

Abstract Background: While pre-existing cardiovascular disease (CVD) appears to be associated with poor outcomes in patients with Coronavirus Disease 2019 (COVID-19), data on patients with CVD and concomitant cancer is limited. Evaluate the effect of underlying CVD and CVD risk factors with cancer history on in-hospital mortality in those with COVID-19.Methods: Data from symptomatic adults hospitalized with COVID-19 at 86 hospitals in the US enrolled in the American Heart Association’s COVID-19 CVD Registry was analyzed. The primary exposure was cancer history. The primary outcome was in-hospital death. Multivariable logistic regression models were adjusted for demographics, CVD risk factors, and CVD. Interaction between history of cancer with concomitant CVD and CVD risk factors were tested.Results: Among 8222 patients, 892 (10.8%) had a history of cancer and 1501 (18.3%) died. Cancer history had significant interaction with CVD risk factors of age, body mass index (BMI), and smoking history, but not underlying CVD itself. History of cancer was significantly associated with increased in-hospital death (among average age and BMI patients, adjusted odds ratio [aOR]=3.60, 95% confidence interval [CI]: 2.07-6.24; p<0.0001 in those with a smoking history and aOR=1.33, 95%CI: 1.01 - 1.76; p=0.04 in non-smokers). Among the cancer subgroup, prior use of chemotherapy within 2 weeks of admission was associated with in-hospital death (aOR=1.72, 95%CI: 1.05-2.80; p=0.03). Underlying CVD demonstrated a numerical but statistically nonsignificant trend toward increased mortality (aOR=1.18, 95% CI: 0.99 - 1.41; p=0.07).Conclusion: Among hospitalized COVID-19 patients, cancer history was a predictor of in-hospital mortality. Notably, among cancer patients, recent use of chemotherapy, but not underlying CVD itself, was associated with worse survival. These findings have important implications in cancer therapy considerations and vaccine distribution in cancer patients with and without underlying CVD and CVD risk factors.
Abemaciclib Plus Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer in Premenopausal Women: Subgroup Analysis From the MONARCH 2 Trial
Neven, Patrick , Tolaney, Sara M. , Iwata, Hiroji, Lu, Yi , Haddad, Nadine , Hurt, Karla, Rugo, Hope S. , Iwata, Hiroji , Toi, Masakazu , Goetz, Matthew P. , Kaufman, Peter A. , Sledge, George W.

Mayo Clinic

No container title available | June 11, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-601421/v1 Get It

Abstract Background: In MONARCH 2, abemaciclib plus fulvestrant significantly improved median progression-free survival (PFS, 16.4 vs 9.3 months, hazard ratio [HR], 0.553) and overall survival (OS, 46.7 vs 37.3 months; HR, 0.757) compared with placebo plus fulvestrant in hormone receptor-positive (HR-positive), human epidermal growth factor receptor 2-negative (HER2-negative) advanced breast cancer (ABC) patients who were endocrine therapy (ET) resistant, regardless of menopausal status. Here, we report findings in the premenopausal subgroup of the MONARCH 2 trial. Methods: The premenopausal subgroup included patients with natural menstrual bleeding who received a gonadotropin-releasing hormone agonist at least 4 weeks prior to study treatment start date and for the entire study duration. Of the 669 patients enrolled in the MONARCH 2 trial, 114 were premenopausal (abemaciclib plus fulvestrant, n=72; placebo plus fulvestrant, n=42), and were included in this analysis. The primary objective was investigator-assessed PFS and secondary objectives were OS, objective response rate, and safety and tolerability. Exploratory analyses included time to second disease progression (PFS2), time to chemotherapy (TTC), and chemotherapy-free survival (CFS). Results: At the primary objective cutoff (14 February, 2017), median PFS was not reached for the abemaciclib plus fulvestrant arm versus 10.52 months for the placebo plus fulvestrant arm (HR, 0.415; 95% CI, 0.246-0.698). At the pre-specified OS interim cutoff (20 June, 2019), median PFS was 28.6 months in the abemaciclib plus fulvestrant arm compared with 10.26 months in the placebo plus fulvestrant arm (HR, 0.477; 95% CI, 0.302-0.755). OS benefit was observed in the abemaciclib plus fulvestrant compared to fulvestrant alone (HR, 0.689; 95% CI, 0.379-1.252, median, not reached vs 47.3 months). Improvements were also observed for the exploratory outcomes of PFS2 (HR, 0.599), TTC (HR, 0.674), and CFS (HR, 0.642) with the addition of abemaciclib to fulvestrant. The safety profile was generally consistent with results disclosed previously. Conclusions: Results of the premenopausal subgroup in the MONARCH 2 trial were consistent with the improved clinical outcomes observed in the intent-to-treat population. The analysis provides support for the use of abemaciclib plus fulvestrant (with ovarian suppression) as an effective treatment option for premenopausal patients with HR+, HER2- ABC who are ET-resistant. Clinical trial registration: NCT02107703. Registered 08 April 2014- Retrospectively registered, https://clinicaltrials.gov/ct2/show/NCT02107703
Patient-Reported Outcomes in a Randomized Trial of Closed-Loop Control: The Pivotal International Diabetes Closed-Loop Trial
Kudva, Yogish C. , Laffel, Lori M. , Brown, Sue A. , Raghinaru, Dan, Pinsker, Jordan E. , Ekhlaspour, Laya , Messer, Laurel H. , Kovatchev, Boris , Lum, John W. , Gonder‐Frederick, Linda , Anderson, Stacey M. , Emory, Emma, Voelmle, Mary, Conshafter, Katie, Morris, Kim, Mitchell, Harry, Calvo, Kayla, Wakeman, Christian, Breton, Marc D. , Ambler-Osborn, Louise, Flint, Emily, Kim, Kenny, Roethke, Lindsay, Church, Mei Mei , André, Camille , Piper, Molly, Lam, David W. , O’Malley, Grenye , Levister, Camilla, Ogyaadu, Selassie, Lovett, Jessica, Simha, Vinaya , Dadlani, Vikash, McCrady-Spitzer, Shelly , Reid, Corey, Forlenza, Gregory P. , Alonso, G. Todd, Slover, Robert H., Jost, Emily , Berget, Cari , Towers, Lindsey, Rossick-Solis, Alex, Buckingham, Bruce A. , Jacobson, Tali, Town, Marissa, Tabatabai, Ideen , Keller, Jordan, Salas, Evalina, Dassau, Eyal , Passman, Samantha, Campos, Tiffany, Kollman, Craig, Murphy, Carlos, Patibandla, Nandan, Borgman, Sarah, Arreaza-Rubín, Guillermo , Green, Neal, Reznik, Yves , Janicek, Robert, Gabrielson, Deanna, Belle, Steven H., Castle, Jessica R. , Legault, Laurent , Wysham, Carol , Eggerman, Thomas L., Messer, Laurel H , Lum, John , Forlenza, Gregory P , Kovatchev, Boris , Buckingham, Bruce , Levy, Carol J. , Beck, Roy W. , Oliveri, Mary Clancy , Isganaitis, Elvira , Kumari, Kanchan, Wadwa, R Paul , Doyle, Francis J. , Kollman, Craig , Renard, Eric , Cobelli, Claudio , Green, Jennifer Greif , Willi, Steven Matthew

Mayo Clinic

Diabetes Technology & Therapeutics | June 11, 2021 | Volume: 23 | Issue: 10 | Pages: 673-683

10.1089/dia.2021.0089 | PMID 34115959 Get It

Background: Closed-loop control (CLC) has been shown to improve glucose time in range and other glucose metrics; however, randomized trials >3 months comparing CLC with sensor-augmented pump (SAP) therapy are limited. We recently reported glucose control outcomes from the 6-month international Diabetes Closed-Loop (iDCL) trial; we now report patient-reported outcomes (PROs) in this iDCL trial. Methods: Participants were randomized 2:1 to CLC ( N = 112) versus SAP ( N = 56) and completed questionnaires, including Hypoglycemia Fear Survey, Diabetes Distress Scale (DDS), Hypoglycemia Awareness, Hypoglycemia Confidence, Hyperglycemia Avoidance, and Positive Expectancies of CLC (INSPIRE) at baseline, 3, and 6 months. CLC participants also completed Diabetes Technology Expectations and Acceptance and System Usability Scale (SUS). Results: The Hypoglycemia Fear Survey Behavior subscale improved significantly after 6 months of CLC compared with SAP. DDS did not differ except for powerless subscale scores, which worsened at 3 months in SAP. Whereas Hypoglycemia Awareness and Hyperglycemia Avoidance did not differ between groups, CLC participants showed a tendency toward improved confidence in managing hypoglycemia. The INSPIRE questionnaire showed favorable scores in the CLC group for teens and parents, with a similar trend for adults. At baseline and 6 months, CLC participants had high positive expectations for the device with Diabetes Technology Acceptance and SUS showing high benefit and low burden scores. Conclusion: CLC improved some PROs compared with SAP. Participants reported high benefit and low burden with CLC. Clinical Trial Identifier: NCT03563313.
Subconjunctival Orbital Fat Prolapse: Diagnosis and Management
Skorin, Leonid

Mayo Clinic

Optometric Clinical Practice | June 11, 2021 | Volume: 1 | Issue: 1 | Pages: No page available

10.37685/uiwlibraries.2575-7717.1.1.1020 Get It

Primary outcome analysis of invasive disease-free survival for monarchE: abemaciclib plus adjuvant endocrine therapy for high-risk early breast cancer
O’Shaughnessy, Joyce , Rastogi, Priya , Im, Y-H, Shao, Z-M, Lehtinen, PL Kellokumpu, Andersson, Michael , Tamura, Kenji , Steger, Guenther G. , Cox, Joanne, Forrester, Tammy , Sherwood, S. , Li, X , Reinisch, Mattea , Johnston, Stephen , Martín, Miguel , Harbeck, Nadia , Toi, Masakazu , Im, Y-H, Huang, Chiun‐Sheng , Tryakin, A. , Goetz, Matthew P. , Rugo, Hope S. , Senkus, Elżbieta , Testa, Laura , Mastro, Lucia Del , Wei, Ran

Mayo Clinic

Senologie - Zeitschrift für Mammadiagnostik und -therapie | June 11, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1055/s-0041-1730206 Get It

Bilateral Subcutaneous Lipomas: The Potential of Point-Of-Care Ultrasonography as a Diagnostic Tool in Dermatology
Dhaliwal, Gurman , Swanson, David C. , Swanson, David L

Mayo Clinic

Dermatologic Surgery | June 11, 2021 | Volume: 47 | Issue: 9 | Pages: 1328-1329

10.1097/dss.0000000000003021 | PMID 34115676 Get It

Venetoclax for the treatment of multiple myeloma: Outcomes outside of clinical trials
Sidiqi, M Hasib , Kumar, Shaji , Leung, Nelson , Muchtar, Eli , Gonsalves, Wilson I. , Kourelis, Taxiarchis , Warsame, Rahma , Lacy, Martha Q. , Kyle, Robert A. , Hobbs, Miriam, Dingli, David , Hayman, Suzanne R. , Kapoor, Prashant , Al Saleh, Abdullah S , Kumar, Shaji K , Leung, Nelson , Muchtar, E , Gonsalves, Wilson , Kourelis, Taxiarchis , Warsame, Rahma , Dispenzieri, Angela , Gertz, Morie A , Rajkumar, S Vincent , Sidiqi, M Hasib , Dingli, David , Saleh, Abdullah S. Al , Jevremović, Dragan , Buadi, Francis K. , Go, Ronald S. , Dispenzieri, Angela , Gertz, Morie A. , Rajkumar, S. Vincent

Mayo Clinic

American Journal of Hematology | June 11, 2021 | Volume: 96 | Issue: 9 | Pages: 1131-1136

10.1002/ajh.26269 | PMID 34115387 Get It

AbstractMultiple myeloma (MM) remains an incurable disease despite incorporation of novel agents. Venetoclax, a B‐cell lymphoma 2 (BCL‐2) inhibitor is approved for some hematologic malignancies but not yet for MM, although clinical trials have shown efficacy in patients with MM, particularly those harboring t(11;14). We reviewed the medical records of relapsed and/or refractory MM patients to study the efficacy and safety of venetoclax used outside of clinical trials at Mayo Clinic between December, 2016 and March, 2019. The data cut‐off date was August 06, 2020. We identified 56 patients of whom 42 (75%) harbored t(11;14). The median number of prior therapies was six (range 1–15) and 14% of patients had received ≥10 prior lines of therapy. Fifty‐three (95%) patients were refractory to an immunomodulatory drug and proteasome inhibitor. Venetoclax was used as monotherapy or doublet, in combination with dexamethasone in 55% (n = 31) and a triplet or quadruplet in 45% of patients. No patient experienced tumor lysis syndrome. Overall response rate in 52 evaluable patients was 44%. The median time to best response was 2 months and median duration of response was 13.6 months. The median PFS for the entire cohort was 5.8 (95% CI 4.9–10.3) months and median OS was 28.4 (95% CI 14.6‐not reached) months. The presence of t(11;14) was associated with improved PFS (median 9.7 months vs. 4.2 months, p = 0.019) and OS (median not reached vs. 10.8 9 months, p = 0.015). Venetoclax demonstrates encouraging activity in heavily‐treated patients with relapsed/refractory MM, particularly the t(11;14) patient‐population.
Precautionary strategy for high‐risk airway bleeding cases during robotic‐assisted bronchoscopy
Fernández-Bussy, Sebastián , Abia‐Trujillo, David , Patel, Neal M. , Pascual, Jorge M., Majid, Adnan , Reisenauer, Janani , Reisenauer, Janani S, Abia-Trujillo, David , Folch, Erik E.

Mayo Clinic

Respirology Case Reports | June 11, 2021 | Volume: 9 | Issue: 7 | Pages: No page available

10.1002/rcr2.794 | PMID 34136261 Get It

AbstractBronchoscopy in thrombocytopenic patients remains a controversial topic as traditionally varying platelet thresholds have been stablished as “safe,” ranging from 20,000 to 50,000. A lower threshold may be safe for a routine airway inspection with bronchoalveolar lavage but will be far from safe for more invasive interventions such as needle biopsy, transbronchial biopsy, or cryo‐biopsy. Currently, a minimal platelet threshold during robotic‐assisted bronchoscopy (RAB) has not been established. In addition, the absolute platelet number does not guarantee appropriate platelet function. The literature regarding the safety of bronchoscopy and its bleeding risk, considering broader and more functional tests such as thromboelastography (TEG), is also lacking. We present our RAB approach to safely sample lung nodules in a patient with thrombocytopenia. Our precautionary strategy for high‐risk bleeding cases during RAB utilizing TEG and parallel flexible bronchoscopy with segmental balloon occlusion may be an appropriate technique to minimize bleeding risk.